Grand Hospital de Charleroi

Charleroi 6000

1 studies enrolling now · 7 studies all time

What they study most

Advanced Endometrial Cancer, Castration-resistant Prostate Cancer, Chronic Lymphocytic Leukemia, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Cancer, Hepatocellular Carcinoma, Myelofibrosis, Non Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Post Essential Thrombocythemia Myelofibrosis

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) — Recruiting now
• Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck — Running, not enrolling
• A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) — Stopped early
• A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors — Stopped early
• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) — Stopped early
• Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies — Completed
• GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer — Withdrawn before enrolling